Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
3420172 | Revue de Pneumologie Clinique | 2006 | 5 Pages |
Abstract
There are few reports in the literature on use of linezolid in cystic fibrosis patients. Writing internal guidelines for our department has enabled standardized use: 600 mg b.i.d. p.o. for 14 days as second-line treatment for bronchial exacerbation of S. aureus infection.
Related Topics
Health Sciences
Medicine and Dentistry
Infectious Diseases
Authors
D. Betton, A.-C. Gairard-Dory, R. Kessler, F. Jehl, V. Rosner, E. Weitzenblum, L. Beretz,